Literature DB >> 18369774

Principles of Dicer substrate (D-siRNA) design and function.

Mohammed Amarzguioui1, John J Rossi.   

Abstract

An efficient RNAi largely depends on optimal design of the siRNA. In recent studies, Dicer substrates were found to be more potent than classical synthetic 21-mer siRNAs, suggesting a coupling of the Dicer-mediated processing step to the efficient assembly of the silencing complex, RISC. We describe the fundamental principles and experimental results leading to optimal Dicer substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18369774     DOI: 10.1007/978-1-59745-191-8_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  15 in total

1.  Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.

Authors:  Sivakamasundari Pichu; Swapna Krishnamoorthy; Bi Zhang; Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Pharmacol Res       Date:  2011-09-10       Impact factor: 7.658

Review 2.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

3.  shRNA expression constructs designed directly from siRNA oligonucleotide sequences.

Authors:  Tuva Barøy; Kirsten Sørensen; Mona Mari Lindeberg; Eirik Frengen
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

4.  Humanized Lewis-Y specific antibody based delivery of STAT3 siRNA.

Authors:  Yuelong Ma; Claudia M Kowolik; Piotr M Swiderski; Marcin Kortylewski; Hua Yu; David A Horne; Richard Jove; Otavia L Caballero; Andrew J G Simpson; Fook-Thean Lee; Vinochani Pillay; Andrew M Scott
Journal:  ACS Chem Biol       Date:  2011-07-26       Impact factor: 5.100

5.  Long double-stranded multiplex siRNAs for dual genes silencing.

Authors:  Wei Peng; Jianxin Chen; Yinchao Qin; Zhenjun Yang; York Yuanyuan Zhu
Journal:  Nucleic Acid Ther       Date:  2013-05-08       Impact factor: 5.486

6.  Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Authors:  Carla L Esposito; Laura Cerchia; Silvia Catuogno; Gennaro De Vita; Justin P Dassie; Gianluca Santamaria; Piotr Swiderski; Gerolama Condorelli; Paloma H Giangrande; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2014-01-20       Impact factor: 11.454

7.  Stealth oxime ether lipid vesicles promote delivery of functional DsiRNA in human lung cancer A549 tumor bearing mouse xenografts.

Authors:  Anu Puri; Faisal Ibrahim; André O'Reilly Beringhs; Camryn Isemann; Paul Zakrevsky; Abigail Whittenburg; Derek Hargrove; Tapan Kanai; Rebecca S Dillard; Natalia de Val; Michael H Nantz; Xiuling Lu; Bruce A Shapiro
Journal:  Nanomedicine       Date:  2022-06-04       Impact factor: 6.096

8.  RORC2 gene silencing in human Th17 cells by siRNA: design and evaluation of highly efficient siRNA.

Authors:  Mazdak Ganjalikhani Hakemi; Kamran Ghaedi; Alireza Andalib; Vida Homayouni; Mohsen Hosseini; Abbas Rezaei
Journal:  Avicenna J Med Biotechnol       Date:  2013-01

9.  Deep Sequencing Analyses of DsiRNAs Reveal the Influence of 3' Terminal Overhangs on Dicing Polarity, Strand Selectivity, and RNA Editing of siRNAs.

Authors:  Jiehua Zhou; Min-Sun Song; Ashley M Jacobi; Mark A Behlke; Xiwei Wu; John J Rossi
Journal:  Mol Ther Nucleic Acids       Date:  2012-04-03       Impact factor: 10.183

Review 10.  Coupling Aptamers to Short Interfering RNAs as Therapeutics.

Authors:  Laura Cerchia; Carla Lucia Esposito; Simona Camorani; Silvia Catuogno; Vittorio de Franciscis
Journal:  Pharmaceuticals (Basel)       Date:  2011-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.